Long-Term Enzyme Replacement Therapy for Pompe Disease With Recombinant Human Alpha-glucosidase Derived From Chinese Hamster Ovary Cells

Abstract

Pompe disease is a rare autosomal recessive myopathy due to the deficiency of lysosomal acid alpha-glucosidase. Clinical phenotypes range from the severe classic infantile form (hypotonia and hypertrophic cardiomyopathy), to milder late onset forms (skeletal myopathy and absence of significant heart involvement). Enzyme replacement therapy with recombinant human alpha-glucosidase derived from either rabbit milk or Chinese hamster ovary cells has been introduced and is undergoing clinical trials. Reported is a long-term follow-up of 3 Pompe patients presenting without cardiomyopathy, treated with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. This study suggests that enzyme replacement therapy can lead to significant motor and respiratory improvement in the subgroup of patients who start the therapy before extensive muscle damage has occurred. The recombinant enzyme derived from Chinese hamster ovary cells, administered at doses significantly higher than previously reported, appears to have the same safety as the drug derived from rabbit milk.

Keywords

enzyme replacement therapy Pompe disease glycogenosis type II

Get full access to this article

View all access options for this article.

References

Hirschhorn R. , Reuser Ajj. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency . In: Scriver CR , Sly WS , Childs, B , et al, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3389-3420.

Kishnani PS , Howell RR Pompe disease in infants and children. J Pediatr. 2004;144(5 suppl):S35-S43.

Van den Hout HM , Hop W. , van Diggelen OP , et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112: 332-340.

Hagemans ML , Winkel LP , Van Doorn PA , et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain. 2005;128:671-677.

Winkel LP , Hagemans ML , van Doorn PA , et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol. 2005;252:875-884.

Slonim AE , Bulone L. , Ritz S. , Goldberg T. , Chen A. , Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr. 2000;137:283-285.

Van den Hout H. , Reuser AJ , Vulto AG , Loonen MC , Cromme-Dijkhuis A. , Van der Ploeg AT Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000; 56:397-398.

Van den Hout JM , Reuser AJ , de Klerk JB , Arts WF , Smeitink JA , Van der Ploeg AT Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis. 2001;24:266-274.

Amalfitano A. , Bengur AR , Morse RP , et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001 ;3:132-138.

10.

Van den Hout JM , Kamphoven JH , Winkel LP , et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113:e448-e457.

11.

Winkel LP , Van den Hout JM , Kamphoven JH , et al. Enzyme replacement therapy in late onset Pompe's disease: a 3-year follow-up. Ann Neur. 2004;55:495-502.

12.

Klinge L. , Straub V. , Neudorf U. , Voit T. Enzyme replacement therapy in classical infantile Pompe disease: results of a 10-month follow-up study. Neuropediatrics. 2005;36:6-11.

13.

Klinge L. , Straub V. , Neudorf U. , et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord. 2005;15:24-31.

14.

Brooke MH , Griggs RC , Mendell JR , Fenichel GM , Shumate JB , Pellegrino RJ et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol . Muscle Nerve 1981;4:186-197.

15.

Haley SM , Fragala MA , Aseltine R. , Ni P. , Skrinar AM Development of a disease-specific disability instrument for Pompe disease . Pediatr Rehabil. 2003;6:77-84.

16.

Hagemans ML , Winkel LP , Hop WC , Reuser AJ , Van Doorn PA , Van der Ploeg AT Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64:2139-2141.

17.

Raben N. , Danon M. , Gilbert AL , et al. Enzyme replacement therapy in the mouse model of Pompe disease . Mol Genet Metab. 2003;80:159-169.

18.

Reuser AJ , Van Den Hout H. , Bijvoet AG , et al. Enzyme therapy for Pompe disease: from science to industrial enterprise. Eur J Pediatr. 2002;161:S106-S111.

19.

Sun B. , Zhang H. , Franco LM , et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther . 2005;11:889-898.

20.

Parenti G. , Zuppaldi A. , Tuzzi MR , et al. Alpha-glucosidase enhancement in fibroblasts from patients with Pompe disease. J Inherit Metab Dis. 2005;28(suppl 1 383-P):193.